<DOC>
	<DOCNO>NCT02171130</DOCNO>
	<brief_summary>Up two hundred ( 200 ) adult patient T1D age 18 75 year select inclusion study . The target obtain treatment response user-experience data follow use AMG504-1 treat episode hypoglycemia . The population enrich include participant suffer impaired hypoglycemia awareness .</brief_summary>
	<brief_title>Clinical Usability Intranasal Glucagon Treatment Hypoglycemia</brief_title>
	<detailed_description>This study propose evaluate effectiveness intranasal ( IN ) glucagon administer clinical use condition treat episode hypoglycemia person T1D . This study also aim assess ease caregiver administer experimental medication treatment hypoglycemic event . The study also generate data patient ' assessment local tolerability provide information immunogenicity AMG504-1 regard potential development anti-glucagon antibody .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Male Female Person diabetes ( PWD ) live frequent contact one caregiver available administer glucagon case episode severe moderate hypoglycemia With history type 1 diabetes &gt; 1 year At least 18 year age old 75 year Body mass index ( BMI ) great equal 18.50 35.00 kg/m2 . PWD otherwise healthy accord medical history , general physical examination ( include vital sign ) , nasal examination , laboratory test ( biochemistry , hematology , urinalysis ) . For female subject , urine pregnancy test must negative . Presence history pheochromocytoma ( i.e . adrenal gland tumor ) insulinoma . Use daily systemic betablockers , indomethacin , warfarin anticholinergic drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Anti-glucagon Antibody</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>